India Approves Donanemab for Alzheimer’s, but Experts Warn of High Costs and Access Barriers
India has approved Eli Lilly’s donanemab for patients with mild cognitive impairment or mild Alzheimer’s disease, but experts warn of high costs and access barriers. The drug has shown promising results in clinical trials, slowing cognitive and functional decline by around 35%. However, its real-world impact may be limited by its premium price tag.